Ligand-directed trafficking of receptor stimulus

Pharmacological Reports

Volumn 66, Issue 6, 2014, Pages 1011-1021

  Chilmonczyk, Zdzisław ^a   Bojarski, Andrzej J ^b   Sylte, Ingebrigt ^c  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Biased agonism; Biased signalling; Ligand directed receptor trafficking; Stimulus trafficking

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPRENOLOL; ARIPIPRAZOLE; BETA ADRENERGIC RECEPTOR; BETA ARRESTIN; BETA ARRESTIN 2; CALCIUM SENSING RECEPTOR; CARAZOLOL; CARVEDILOL; DOPAMINE 2 RECEPTOR; F 13714; F 15599; G PROTEIN COUPLED RECEPTOR; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; PINDOLOL; PROPRANOLOL; PROTEIN KINASE P60; SALBUTAMOL; SALMETEROL; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNC 0006; UNC 9975; UNC 9994; UNCLASSIFIED DRUG; UNINDEXED DRUG; LIGAND; PROTEIN;

DRUG ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART FAILURE; HUMAN; INTERNALIZATION; INTRACELLULAR SIGNALING; LIGAND DIRECTED RECEPTOR TRAFFICKING; NEUROPHARMACOLOGY; NONHUMAN; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PSYCHOPHARMACOLOGY; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; BIOLOGICAL MODEL; DRUG DESIGN; METABOLISM;

DRUG DESIGN; HUMANS; LIGANDS; MODELS, BIOLOGICAL; PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84908665597     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.06.006     Document Type: Review

References (89)

1. T.K. Bjarnadóttir, D.E. Gloriam, S.H. Hellstrand, H. Kristiansson, R. Fredriksson, and H.B. Schiöth Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse Genomics 88 2006 263 273 (Pubitemid 44278529)
2. B.K. Kobilka G protein coupled receptor structure and activation Biochim Biophys Acta 1768 2007 794 807 (Pubitemid 46452546)
3. N. Wettschureck, and S. Offermanns Mammalian G proteins and their cell type specific functions Physiol Rev 85 2005 1159 1204 (Pubitemid 41362268)
4. L.E. Limbird Cell surface receptors: a short course on theory and methods 1986 Martinus Nijhoff Publishing Boston
5. M. Frank, L. Thümer, J.M. Lohse, and M. Bünemann G protein activation without subunit dissociation depends on a Gαi-specific region J Biol Chem 280 2005 24584 24590 (Pubitemid 40934546)
6. B. Hollins, S. Kuravi, G.J. Digby, and N.A. Lambert The c-terminus of GRK3 indicates rapid dissociation of G protein heterotrimers Cell Signal 21 2009 1015 1021
7. P. Chidiac, T.E. Hebert, M. Valiquette, M. Dennis, and M. Bouvier Inverse agonist activity of β-adrenergic antagonists Mol Pharmacol 45 1994 490 499 (Pubitemid 24094939)
8. T. Costa, Y. Ogino, P.J. Munson, H.O. Onaran, and D. Rodbard Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand Mol Pharmacol 41 1992 549 560
9. R.J. Lefkowitz, S. Cotecchia, P. Samama, and T. Costa Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins Trends Pharmacol Sci 14 1993 303 307 (Pubitemid 23242583)
10. 35S]GTPγS binding assay: approaches and applications in pharmacology Life Sci 74 2003 489 508 (Pubitemid 37377904)
11. E. Kostenis G proteins in drug screening: from analysis of receptor-G protein specificity to manipulation of GPCR-mediated signalling pathways Curr Pharm Des 12 2006 1703 1715
12. W.M. Oldham, and H.E. Hamm Heterotrimeric G protein activation by G-protein-coupled receptors Nat Rev Mol Cell Biol 9 2008 60 71
13. D. Voet, J.G. Voet, and C.W. Pratt Principles of biochemistry: international student version 4th edition 2013 John Wiley & Sons Singapore Pvt. Ltd.
14. S.-C. Hsiung, M. Adlersberg, V. Arango, J.J. Mann, H. Tamir, and K.P. Liu Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase J Neurochem 87 2003 182 194 (Pubitemid 37210652)
15. 1A receptor-regulated signal transduction pathways in brain Cell Signal 22 2010 1406 1412
16. T. Adayev, Y. El-Sherif, M. Barua, and P. Banarjee Agonist stimulation of the serotonin 1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells J Neurochem 72 1999 1489 1496 (Pubitemid 29140820)
17. + channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons Neuron 19 1997 687 695 (Pubitemid 27430754)
18. T.P. Kenakin Cellular assays as portals to seven-transmembrane receptor-based drug discovery Nat Rev Drug Discov 8 2009 617 626
19. T.P. Kenakin Functional selectivity and biased receptor signaling J Pharmacol Exp Ther 336 2011 296 302
20. S. Rajagopal, K. Rajagopal, and R.J. Lefkowitz Teaching old receptors new tricks: biasing seven-transmembrane receptors Nat Rev Drug Discov 9 2010 373 386
21. A.R.B. Thomsen, M. Hvidtfeldt, and H. Bräuner-Osborne Biased agonism of the calcium-sensing receptor Cell Calcium 51 2012 107 116
22. J.S. Gutkind Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors Sci STKE 2000 RE1
23. T.P. Kenakin Inverse, protean, and ligand-selective agonism: matters of receptor conformation FASEB J 15 2001 598 611
24. T.P. Kenakin Pharmacological onomastics: what's in a name? Br J Pharmacol 153 2008 432 438 (Pubitemid 351199005)
25. D. Gesty-Palmer, M. Chen, E. Reiter, S. Ahn, C.D. Nelson, and S. Wang et al. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation J Biol Chem 281 2006 10856 10864 (Pubitemid 43855508)
26. H. Wei, S. Ahn, S.K. Shenoy, S.S. Karnik, L. Hunyady, and L.M. Luttrell et al. Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 Proc Natl Acad Sci USA 100 2003 10782 10787 (Pubitemid 37140105)
27. B.A. Evans, M. Sato, M. Sarwar, D.S. Hutchinson, and R.J. Summers Ligand-directed signalling at β-adrenoceptors Br J Pharmacol 159 2010 1022 1038
28. T. Kenakin, and A. Christopoulos Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat Rev Drug Discov 12 2013 205 216
29. J.D. Urban, W.P. Clarke, M. Von Zastrow, D.E. Nichols, B. Kobilka, and H. Weinstein et al. Functional selectivity and classical concepts of quantitative pharmacology J Pharmacol Exp Ther 269 2007 290 296
30. C. Hoffmann, A. Zürn, M. Bünemann, and M.J. Lohse Conformational changes in G-protein-coupled receptors - the quest for functionally selective conformations is open Br J Pharmacol 153 2008 S358 S366
31. B.K. Kobilka, and X. Deupi Conformational complexity of G-protein-coupled receptors Trends Pharmacol Sci 28 2007 397 406 (Pubitemid 47087966)
32. J.G. Baker, S.J. Hill, and R.J. Summers Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling Trends Pharm Sci 32 2011 227 234
33. M.I. Simon, M.P. Stratham, and N. Gautam Diversity of G proteins in signal transduction Science 252 1991 802 808 (Pubitemid 121000516)
34. V. Katritch, V. Cherezov, and R.C. Stevens Structure-function of the G protein-coupled receptor superfamily Annu Rev Pharmacol Toxicol 53 2013 531 556
35. A.S.V. Burgen Conformational changes and drug action Fed Proc 40 1981 2723 2728 (Pubitemid 12193920)
36. S.M. DeWire, S. Ahn, R.J. Lefkowitz, and S.K. Shenoy β-Arrestins and cell signaling Annu Rev Physiol 69 2007 483 510
37. A. Tohgo, K.L. Pierce, E.W. Choy, R.J. Lefkowitz, and L.M. Luttrell β-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation J Biol Chem 277 2002 9429 9943
38. A. Tohgo, E.W. Choy, D. Gesty-Palmer, K.L. Pierce, S. Laporte, and R.H. Oakley et al. The stability of the G protein-coupled receptor-β-arrestin interaction determines the mechanism and functional consequence of ERK activation J Biol Chem 278 2003 6258 6267 (Pubitemid 36800882)
39. S. Ahn, S.K. Shenoy, H. Wei, and R.J. Lefkowitz Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor J Biol Chem 279 2004 35518 35525 (Pubitemid 39100552)
40. A.K. Shukla, K. Xiao, and R.J. Lefkowitz Emerging paradigms of β-arrestin dependent seven transmembrane receptor signaling Trends Biochem Sci 36 2011 457 469
41. R.W. Walters, A.K. Shukla, J.J. Kovacs, J.D. Violin, S.M. DeWire, and C.M. Lam et al. Beta-arrestin1 mediates nicotinic acid induced flushing, but not its antilipolytic effect, in mice J Clin Invest 119 2009 1312 1321
42. G. Semple, P.J. Skinner, T. Gharbaoui, Y.J. Shin, J.K. Jung, and M.C. Cherrier et al. 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice J Med Chem 51 2008 5101 5108
43. J.G. Baker, I.P. Hall, and S.J. Hill Agonist and inverse agonist actions of β-blockers at the human β2-adrenoceptor provide evidence for agonist-directed signaling Mol Pharmacol 64 2003 1357 1369 (Pubitemid 37532226)
44. E.J. Kunkel, I. Plavec, D. Nguyen, J. Melrose, E.S. Rosler, and L.T. Kao et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models Assay Drug Dev Technol 2 2004 431 441 (Pubitemid 39276284)
45. M.T. Drake, J.D. Violin, E.J. Whalen, J.W. Wisler, S.K. Shenoy, and R.J. Lefkowitz β-Arrestin-biased agonism at the β-2 adrenergic receptor J Biol Chem 283 2008 5669 5676
46. R. Seifert, and S. Dove Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities Mol Pharmacol 75 2009 13 18
47. J.W. Wisler, S.M. DeWire, E.J. Whalen, J.D. Violin, M.T. Drake, and S. Ahn et al. A unique mechanism of beta-blocker action: carvedilol stimulates β-arrestin signaling Proc Natl Acad Sci USA 104 2007 16657 16662 (Pubitemid 350211072)
48. M. Azzi, P.G. Charest, S. Angers, G. Rousseau, T. Kohout, and M. Bouvier et al. β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors Proc Natl Acad Sci USA 100 2003 11406 11411 (Pubitemid 37205948)
49. M. Sato, T. Horinouchi, D.S. Hutchinson, B.A. Evans, and R.J. Summers Ligand-directed signaling at the β3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR 59230A) relative to receptor agonists Mol Pharmacol 72 2007 1359 1368 (Pubitemid 350012609)
50. 3- adrenoceptor Mol Pharmacol 74 2008 1417 1428
51. T. Noma, A. Lemaire, P. Naga, V. Sathyamangla, L. Barki-Harrington, and D.G. Tilley et al. β-Arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection J Clin Invest 117 2007 2445 2458
52. I.-M. Kim, D.G. Tilley, J. Chen, N.C. Salazar, E.J. Whalen, and J.D. Violin et al. Beta-blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation Proc Natl Acad Sci USA 105 2008 14555 14560
53. M. Metra, L.D. Cas, A. Di Lenarda, and P. Poole-Wilson Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev 9 2005 123 130 (Pubitemid 39485473)
54. A.Y. Woo, T.B. Wang, X. Zeng, W. Zhu, D.R. Abernethy, and I.W. Wainer et al. Stereochemistry of an agonist determines coupling preference of β2-adrenoceptor to different G proteins in cardiomyocytes Mol Pharmacol 75 2009 158 165
55. A.W. Kahsai, K. Xiao, S. Rajagopal, S. Ahn, A.K. Shukla, and J. Sun et al. Multiple ligand-specific conformations of the β2-adrenergic receptor Nat Chem Biol 7 2011 692 700
56. O. Kifor, R.J. MacLeod, R. Diaz, M. Bai, T. Yamaguchi, and T. Yao et al. Regulation of MAP kinase by calcium-sensing receptor in bovine parathyroid and CaR-transfected HEK293 cells Am J Physiol Renal Physiol 280 2001 F291 F302
57. B.K. Kobilka, T. Frielle, and S. Collins et al. An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins Nature 329 1987 75 79 (Pubitemid 17125898)
58. 1A receptor Nature 335 1988 358 360
59. G.J. Della Rocca, Y.V. Mukhin, M.N. Garnoyskaya, Y. Daaka, G.J. Clark, and L.M. Luttrel et al. Serotonin 5-HT1A receptor-mediated ERK activation requires calcium/calmodulin-dependent receptor endocytosis J Biol Chem 274 1999 4749 4753
60. B. Stoyanov, S. Volinia, T. Hanck, I. Rubio, M. Loubtchenkoy, and D. Malek et al. Cloning and characterization of a G protein-activated human phosphoinositide-3-kinase Science 269 1995 690 693
61. E. Zwick, C. Wallasch, H. Daub, and A. Ullrich Distinct calcium-dependent pathways of epidermal growth factor receptor transactivation and PYK2 tyrosine phosphorylation in PC12 cells J Biol Chem 274 1999 20989 20996
62. J. Savitz, I. Lucki, and W.C. Drevets 5-HT1A receptor function in major depressive disorder Prog Neurobiol 88 2009 17 31
63. A. Newman-Tancredi, J.-C. Mertell, M.-B. Assié, J. Buritova, E. Lauressergues, and C. Cosi et al. Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist Br J Pharmacol 156 2009 338 353
64. 1A receptor agonist: in vivo profile in neurochemical and behavioural models of serotonergic activity Eur Neuropsychopharmacol 16 2006 S233
65. M.-B. Assié, H. Lomenech, V. Ravailhe, V. Faucillon, and A. Newman-Tancredi Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat Br J Pharmacol 149 2006 170 178 (Pubitemid 44360098)
66. R. Depoortère, A.L. Auclair, L. Bardin, F.C. Colpaert, B. Vacher, and A. Newman-Tancredi F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists Eur Neuropsychopharmacol 20 2010 641 654
67. P. Celada, L. Llado, M.-B. Assié, A. Newman-Tancredi, and F. Artigas F15599, a 5-HT1A agonist that preferentially targets post-synaptic receptors in the frontal cortex: IV. Influence on rat raphe and pyramidal neuronal activity and cortical dopamine release. Neuroscience meeting planner 2007 Society for Neuroscience San Diego, CA 170.27
68. A. Auclair, L. Bardin, R. Depoortère, and A. Newman-Tancredi F15599, a 5-HT1A agonist that preferentially targets post-synaptic receptors in the frontal cortex: III. Activity in radent models of cognition. Neuroscience meeting planner 2007 Society for Neuroscience San Diego, CA 170.24
69. M.-B. Assié, L. Bardin, A.L. Auclair, E. Carilla-Durand, R. Depoortère, and W. Koek et al. F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity Int J Neuropsychopharmacol 13 2010 1285 1298
70. A. Enjalbert, and J. Bockaert Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary Mol Pharmacol 23 1983 576 584 (Pubitemid 13089773)
71. D.J. Roberts, and P.G. Strange Mechanisms of inverse agonist action at D2 dopamine receptors Br J Pharmacol 145 2005 34 42 (Pubitemid 40675546)
72. J.-M. Beaulieu, R.R. Gainetdinov, and M.G. Caron Akt/GSK3 signaling in the action of psychotropic drugs Annu Rev Pharmacol Toxicol 49 2009 327 347
73. J.-M. Beaulieu, T.D. Sotnikova, S. Marion, R.J. Lefkowitz, R.R. Gainetdinov, and M.G. Caron An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior Cell 122 2005 261 273 (Pubitemid 41032989)
74. J.-M. Beaulieu, S. Marion, R.M. Rodriguiz, I.O. Medvedev, T.D. Sotnikova, and V. Ghisi et al. A β-arrestin 2 signaling complex mediates lithium action on behavior Cell 132 2008 125 136
75. L.M. Bohn, R.R. Gainetdinov, T.D. Sotnikova, I.O. Medvedev, R.J. Lefkowitz, and L.A. Dykstra et al. Enhanced rewarding properties of morphine, but not cocaine, in β-arrestin 2 knock-out mice J Neurosci 23 2003 10265 10273 (Pubitemid 37444603)
76. R.R. Gainetdinov, R.T. Premont, L.M. Bohn, R.J. Lefkowitz, and M.G. Garon Desensitization of G protein-coupled receptors and neuronal functions Annu Rev Neurosci 27 2004 107 144 (Pubitemid 39050399)
77. J.A. Allen, J.M. Yost, V. Setola, X. Chen, M.F. Sassano, and M. Chen et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy Proc Natl Acad Sci USA 108 2011 18488 18493
78. C.P. Lawler, C. Prioleau, M.M. Lewis, C. Mak, D. Jiang, and J.A. Schetz et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes Neuropsychopharmacology 20 1999 612 627 (Pubitemid 29189265)
79. R.B. Mailman, and V. Murthy Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 16 2010 488 501
80. J.D. Urban, G.A. Vargas, M. Von Zastrow, and R.B. Mailman Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways Neuropsychopharmacology 32 2007 67 77 (Pubitemid 44967785)
81. B. Masri, A. Salahpour, M. Didriksen, V. Ghisi, J.-M. Beaulieu, and R.R. Gainetdinov et al. Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics Proc Natl Acad Sci USA 105 2008 13656 13661
82. B.L. Roth, D.J. Scheffer, and W.K. Kroeze Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat Rev Drug Discov 3 2004 353 359 (Pubitemid 38499762)
83. E. Kelly Efficacy and ligand bias at the μ-opioid receptor Br J Pharmacol 169 2013 1430 1446
84. C.E. Groer, K. Tidgewell, R.A. Moyer, W.W. Harding, R.B. Rothman, and T.E. Prisinzano et al. An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization Mol Pharmacol 71 2007 549 557 (Pubitemid 46147920)
85. L.M. Bohn, R.J. Lefkowitz, R.R. Gainetdinov, K. Peppel, M.G. Caron, and F.T. Lin Enhanced morphine analgesia in mice lacking β-arrestin 2 Science 286 1999 2495 2498
86. L.M. Bohn, L.A. Dykstra, R.J. Lefkowitz, M.G. Caron, and L.S. Barak Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery Mol Pharmacol 66 2004 106 112 (Pubitemid 38822092)
87. K.M. Raehal, J.K. Walker, and L.M. Bohn Morphine side effects in β-arrestin 2 knockout mice J Pharmacol Exp Ther 314 2005 1195 1201 (Pubitemid 41205984)
88. E.J. Whalen, S. Rajagopal, and R.J. Lefkowitz Therapeutic potential of β-arrestin- and G protein-biased agonists Trends Mol Med 17 2011 126 139
89. T. Kenakin New concepts in pharmacological efficacy at 7TM receptors: IUPHAR Review 2 Br J Pharmacol 168 2013 554 575